Let's Connect

Insights

Mirava Bio is now live in the Netherlands: introducing Mirava Bio BV

We are pleased to announce Mirava Bio BV, our Dutch (...)
See more +

EU Joint Clinical Assessment (JCA): What US Biotechs Need to Know

The EU HTA Regulation introduces a mandatory Joint Clinical Assessment (...)
See more +

Early Access in Europe: Generating Revenue Before Marketing Authorisation

France, Italy, Germany and Switzerland all run early-access schemes that (...)
See more +

From Phase 2 Readout to a European Pricing Agreement: The 10 Gates

A decision-gated map of the European pathway for rare disease, (...)
See more +

Mirava Bio joins the Swiss Biotech Association

We are proud to announce that Mirava Bio is now (...)

See more +

Meet us at the World Orphan Drug Congress Europe 2025

Amsterdam | October 27–28 | Booth S19 Mirava Bio will (...)

See more +

Rethinking Market Entry for Rare-Disease Biotechs: How Mirava Bio is Redefining Go-to-Market in Europe, the Middle East, and Eurasia

By Vincent Lévêque, Co-Founder & CEO, Mirava Bio The Essence (...)

See more +
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.